These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17071154)

  • 21. Aldosterone blockade in cardiovascular disease.
    Struthers AD
    Heart; 2004 Oct; 90(10):1229-34. PubMed ID: 15367532
    [No Abstract]   [Full Text] [Related]  

  • 22. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
    Talatinian A; Chow SL; Heywood JT
    Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE; Marwick TH; Krum H
    Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldosterone target organ protection by eplerenone.
    Rudolph AE; Rocha R; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury.
    Lahmer T; Hermans R; Schmaderer C; Chang J; Stock K; Lutz J; Heemann U; Baumann M
    Kidney Blood Press Res; 2012; 35(6):561-7. PubMed ID: 22890233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathophysiological role of aldosterone in acute renal failure].
    Bobadilla NA
    Rev Invest Clin; 2007; 59(6):470-80. PubMed ID: 18402339
    [No Abstract]   [Full Text] [Related]  

  • 29. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
    Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mineralocorticoid receptor antagonist for renal protection.
    Ma TK; Szeto CC
    Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
    Tylicki L; Lizakowski S; Rutkowski B
    J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
    Pitt B; Stier CT; Rajagopalan S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):164-8. PubMed ID: 14608520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives.
    Epstein M
    Intern Med; 2001 Jul; 40(7):573-83. PubMed ID: 11506295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
    Colussi G; Catena C; Sechi LA
    J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
    Pitt B
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):53-8. PubMed ID: 15134801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.